Published in Blood Cancer J on March 04, 2011
Definition and management of ruxolitinib treatment failure in myelofibrosis. Blood Cancer J (2014) 0.80
The Genomic Impact of DNA CpG Methylation on Gene Expression; Relationships in Prostate Cancer. Biomolecules (2017) 0.75
Epigenetics in Myeloproliferative Neoplasms. J Cell Mol Med (2017) 0.75
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science (2009) 32.97
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature (2010) 8.87
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia (2007) 8.34
UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature (2007) 8.32
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood (2008) 7.73
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 5.95
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet (2010) 4.90
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol (2010) 4.72
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature (2009) 4.60
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A (2010) 4.52
Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol (2009) 4.18
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol (2010) 4.18
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia (2010) 4.09
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol (2011) 4.06
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood (2010) 4.02
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood (2009) 3.69
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia (2009) 3.49
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood (2010) 3.41
Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol (2011) 3.29
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia (2009) 3.23
Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med (2010) 3.20
Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med (1976) 3.18
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia (2008) 3.04
Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia (2009) 2.77
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood (2009) 2.77
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res (2010) 2.69
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia (2010) 2.65
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood (2004) 2.64
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood (2010) 2.61
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood (2008) 2.55
Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci U S A (1967) 2.48
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood (2011) 2.47
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia (2008) 2.35
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol (2010) 2.29
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia (2010) 2.23
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2010) 2.21
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood (2009) 2.18
Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia (2010) 2.01
In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood (2009) 1.90
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol (2010) 1.90
Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood (2009) 1.90
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia (2011) 1.88
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol (2009) 1.88
Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood (1978) 1.83
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol (2009) 1.83
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood (2009) 1.78
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia (2010) 1.75
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia (2010) 1.72
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol (2010) 1.71
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol (2009) 1.69
IDH2 mutations in patients with D-2-hydroxyglutaric aciduria. Science (2010) 1.63
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. Am J Hematol (2010) 1.62
Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood (2010) 1.57
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia (2010) 1.51
Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia (2009) 1.45
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia (2010) 1.44
Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood (1981) 1.40
High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia (2010) 1.38
Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J Biol Chem (2006) 1.37
Retracted ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J Biol Chem (2009) 1.35
WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia (2010) 1.34
Cladribine therapy for systemic mastocytosis. Blood (2003) 1.34
Lnk constrains myeloproliferative diseases in mice. J Clin Invest (2010) 1.29
The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood (2008) 1.28
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood (2010) 1.28
A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia (2010) 1.27
Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia (2010) 1.26
Deregulation of H3K27 methylation in cancer. Nat Genet (2010) 1.23
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood (2010) 1.22
Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol (2010) 1.19
The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia (2010) 1.18
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia (2010) 1.17
Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia (2006) 1.16
Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells (2007) 1.16
Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. Haematologica (2009) 1.16
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood (2010) 1.16
Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol (2007) 1.14
Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia (2009) 1.13
Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol (1990) 8.97
Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol (2000) 4.89
Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood (1999) 4.58
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med (1995) 4.32
Transcription factors, normal myeloid development, and leukemia. Blood (1997) 3.71
Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids (2003) 3.66
Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood (1984) 3.65
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) 3.58
Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet (2000) 3.50
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia (2009) 3.49
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia (2009) 3.23
Mutations and prognosis in primary myelofibrosis. Leukemia (2013) 3.13
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia (2008) 3.04
Turnover of bacterial glutamine synthetase: oxidative inactivation precedes proteolysis. Proc Natl Acad Sci U S A (1981) 2.93
Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature (1997) 2.93
Oxidative damage during aging targets mitochondrial aconitase. Proc Natl Acad Sci U S A (1997) 2.76
Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood (1968) 2.71
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia (2010) 2.65
Critical care in the emergency department: a time-based study. Crit Care Med (1993) 2.59
Protein oxidation. Ann N Y Acad Sci (2000) 2.57
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia (2007) 2.49
The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med (1997) 2.41
Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol (1997) 2.38
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia (2008) 2.35
Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res (1994) 2.34
Oxidative modification of glutamine synthetase. I. Inactivation is due to loss of one histidine residue. J Biol Chem (1983) 2.29
PHF6 mutations in adult acute myeloid leukemia. Leukemia (2010) 2.20
No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol (1998) 2.18
HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J (1999) 2.16
Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med (1990) 2.11
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost (2012) 2.04
Glutamic and aminoadipic semialdehydes are the main carbonyl products of metal-catalyzed oxidation of proteins. Proc Natl Acad Sci U S A (2001) 2.04
Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med (1994) 2.03
Antagonism between C/EBPbeta and FOG in eosinophil lineage commitment of multipotent hematopoietic progenitors. Genes Dev (2000) 2.02
Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood (1996) 2.02
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia (2013) 1.97
Caspase activation is required for terminal erythroid differentiation. J Exp Med (2001) 1.97
Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med (2008) 1.93
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood (1998) 1.90
Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J Biol Chem (2001) 1.89
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia (2011) 1.88
Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene (2011) 1.87
Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein. J Biol Chem (1997) 1.85
Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem (2000) 1.82
Mammalian thioredoxin reductase: oxidation of the C-terminal cysteine/selenocysteine active site forms a thioselenide, and replacement of selenium with sulfur markedly reduces catalytic activity. Proc Natl Acad Sci U S A (2000) 1.82
Conversion of amino acid residues in proteins and amino acid homopolymers to carbonyl derivatives by metal-catalyzed oxidation reactions. J Biol Chem (1989) 1.80
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood (1982) 1.79
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia (2011) 1.79
Oxidative modification of glutamine synthetase. II. Characterization of the ascorbate model system. J Biol Chem (1983) 1.78
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia (2008) 1.78
Epigenetic regulation of normal and malignant hematopoiesis. Oncogene (2007) 1.75
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia (2010) 1.75
A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol (1996) 1.73
Identification of oxidant-sensitive proteins: TNF-alpha induces protein glutathiolation. Biochemistry (2000) 1.70
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia (2013) 1.69
Purification of a protease from Escherichia coli with specificity for oxidized glutamine synthetase. J Biol Chem (1987) 1.68
The Qo site of cytochrome b6f complexes controls the activation of the LHCII kinase. EMBO J (1999) 1.68
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood (1981) 1.68
Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia (2007) 1.67
Iron-dependent oxidation, ubiquitination, and degradation of iron regulatory protein 2: implications for degradation of oxidized proteins. Proc Natl Acad Sci U S A (1998) 1.66
In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions. Mol Cell Biol (2000) 1.66
Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost (1993) 1.65
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia (2013) 1.65
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia (2010) 1.64
A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother (1994) 1.64
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia (2010) 1.63
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia (2009) 1.63
Developmental changes in human megakaryopoiesis. J Thromb Haemost (2013) 1.63
Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver. J Biol Chem (1999) 1.63
Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann Oncol (2002) 1.61
Cardiac arrest presenting with rhythms other than ventricular fibrillation: contribution of resuscitative efforts toward total survivorship. Crit Care Med (1993) 1.61
Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem (1999) 1.60
Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene (2001) 1.59
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol (2005) 1.58